MedTrace Logo

The Triple A Initiative Study ("Aktionsbündnis Akute Atemnot")

NCT02049853 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2015-05-20

No results posted yet for this study

Summary

Acute dyspnea is a common chief complaint of patients presenting to the emergency department. Patients with acute dyspnea display a high mortality rate. In-hospital mortality is as high as 10% during hospitalization and up to 30% within 6 months of follow-up. The Triple A Initiative Study is designed to improve the coordination of care for patients with acute dyspnea alerting the Emergency Medical Service (EMS). We hypothesize that the coordination of care starting at the EMS level including point-of-care testing of the cardiac biomarker NTproBNP will support preclinical and clinical diagnostic clarification. Treatment deriving from earlier diagnostic clarification will reduce length of stay in the hospital, treatment costs and improve patient's outcome.

Conditions

Interventions

DEVICE

NTproBNP measurement with point of care device "Cobash232" in the POCT group

Sponsors & Collaborators

  • Jena University Hospital

    collaborator OTHER

  • City Hospital Fürth

    collaborator OTHER

  • Roche Pharma AG

    collaborator INDUSTRY

  • Bayrisches Rotes Kreuz Fuerth

    collaborator UNKNOWN

  • Johanniter Unfall Hilfe Nürnberg

    collaborator UNKNOWN

  • DRK-Kreisverbandes Jena-Eisenberg-Stadtroda e.V.

    collaborator UNKNOWN

  • Prof. Dr. Michael Christ

    lead OTHER

Principal Investigators

  • Michael Christ, Prof. · Klinikum Nürnberg

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2015-04-30
Completion
2015-05-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02049853 on ClinicalTrials.gov